%0 Journal Article %T Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma %+ Centre Hospitalier Universitaire d'Angers (CHU Angers) %+ CHU Pontchaillou [Rennes] %+ Centre d'Investigation Clinique [Rennes] (CIC) %+ Centre Hospitalier Régional Universitaire de Tours (CHRU Tours) %+ Centre Hospitalier Régional Universitaire de Brest (CHRU Brest) %+ Service d'hématologie clinique [Avicenne] %+ Centre Hospitalier de Blois (CHB) %+ Laboratoire d'Hématologie [CHU Amiens] %+ Service clinique des Maladies du Sang %+ Hôpital Saint-Quentin %+ CHU Amiens-Picardie %A Schmidt-Tanguy, A %A Houot, R %A Lissandre, S %A Abgrall, J.F. %A Casassus, P %A Rodon, P %A Desablens, B %A Marolleau, Jean-Pierre %A Garidi, R %A Lamy, T %A Moles-Moreau, M.-P %A Damaj, G %< avec comité de lecture %@ 1687-9104 %J Advances in Hematology %I Hindawi %V 2014 %P 512508 %8 2014-03-02 %D 2014 %R 10.1155/2014/512508 %M 24723955 %Z Life Sciences [q-bio]Journal articles %X Background. Primary bone lymphoma (PBL) is a rare entity that has only been reviewed in one prospective and small retrospective studies, from which it is difficult to establish treatment guidelines. We prospectively evaluated high-dose or conventional anthracycline-cyclophosphamide dose and radiotherapy for PBL. Patients and Methods. The GOELAMS prospective multicenter study (1986–1998) enrolled adults with localized high-grade PBL according to age and performance status (PS). Patients <60 years received a high-dose CHOP regimen (VCAP) and those ≥60 years a conventional anthracycline-cyclophosphamide regimen (VCEP-bleomycin); all received intrathecal chemotherapy and local radiotherapy. Results. Among the 26 patients included (VCAP: 19; VCEP-bleomycin: 7), 39% had poor PS ≥2. With a median follow-up of 8 years, overall survival, event-free survival, and relapse-free survival were 64%, 62%, and 65%, respectively, with no significant difference between treatment groups. Poor PS was significantly associated with shorter OS and EFS. Conclusions. Our results confirm the efficacy of our age-based therapeutic strategy. High-doses anthracycline-cyclophosphamide did not improve the outcome. VCEP-bleomycin is effective and well tolerated for old patients. The intensification must be considered for patients with PS ≥2, a poor prognostic factor. %G English %2 https://univ-rennes.hal.science/hal-01155268/document %2 https://univ-rennes.hal.science/hal-01155268/file/Results%20of%20a%20Prospective%20Study%20of%20High-Dose.pdf %L hal-01155268 %U https://univ-rennes.hal.science/hal-01155268 %~ INSERM %~ UNIV-PARIS13 %~ UNIV-RENNES1 %~ APHP %~ UNAM %~ HL %~ CIC %~ CIC203 %~ STATS-UR1 %~ UR1-UFR-SVE %~ UR1-HAL %~ UR1-SDV %~ TEST-UNIV-RENNES %~ TEST-UR-CSS %~ UNIV-RENNES %~ SORBONNE-PARIS-NORD %~ UR1-BIO-SA